NCT05655949View on ClinicalTrials.gov

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 13, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2027

Conditions
Bile Duct CancerCholangiocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma MetastaticMetastatic Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Gemcitabine

Intravenous infusion

DRUG

Cisplatin

Intravenous infusion

DRUG

Durvalumab

Intravenous infusion

RADIATION

Yttrium-90

Injection of radiation microsphere beads

Trial Locations (1)

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (2)

AstraZeneca
Sirtex Medical
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Sirtex Medical

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER